Ontario Teachers Pension Plan Board Invests $364,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Ontario Teachers Pension Plan Board acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,547 shares of the biopharmaceutical company’s stock, valued at approximately $364,000.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after purchasing an additional 98,303 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $1,045,822,000. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $577,941,000. Geode Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company’s stock valued at $518,367,000 after buying an additional 59,597 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.7% during the 4th quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock valued at $377,443,000 after acquiring an additional 11,291 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ALNY shares. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $280.00 to $328.00 in a report on Monday, March 24th. Royal Bank of Canada upped their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a report on Friday, March 21st. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a “buy” rating and a $353.00 price target for the company. Finally, Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research note on Monday, March 31st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $315.58.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $234.56 on Friday. The firm has a fifty day moving average of $249.82 and a two-hundred day moving average of $257.36. The firm has a market cap of $30.51 billion, a P/E ratio of -108.09 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.